3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
5
Terminated
2
Unknown
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
15
Endocrine
15
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Uterine Cervical Neoplasms
132
Ovarian Neoplasms
109
Endometrial Neoplasms
80
Uterine Cervical Dysplasia
19
Papillomavirus Infections
17
Breast Neoplasms
16
Fallopian Tube Neoplasms
15
Carcinoma, Ovarian Epithelial
15
Colorectal Neoplasms
13
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Vulvar Neoplasms
10
Neoplasm Metastasis
10
Recurrence
9
Prostatic Neoplasms
9
Endometrial Hyperplasia
9
Cervical Cancer Screening
9
Acquired Immunodeficiency Syndrome
8
Uterine Neoplasms
7
Stomach Neoplasms
7
Squamous Intraepithelial Lesions
6
Locally Advanced Cervical Cancer
6
Anus Neoplasms
6
Vaginal Neoplasms
5
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pelvic Neoplasms
5
Pancreatic Neoplasms
5
Melanoma
5
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Thyroid Cancer, Papillary
×
Gynecologic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled